$2.66
3.62% today
Nasdaq, Apr 29, 06:15 pm CET
ISIN
US01438T1060
Symbol
ALDX
Sector
Industry

Aldeyra Therapeutics, Inc. Stock News

Neutral
GlobeNewsWire
about one hour ago
SAN FRANCISCO, April 29, 2025 (GLOBE NEWSWIRE) -- On April 3, 2025 investors in Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) saw the price of their shares crash over 70% after the company announced that it received a Complete Response Letter (“CRL”) from the FDA for the resubmission of the New Drug Application (“NDA”) of reproxalap, an investigational drug candidate, for the treatment of dry eye d...
Neutral
GlobeNewsWire
about 16 hours ago
NEW YORK, April 28, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against TechTarget, Inc. (NASDAQ:TTGT) and Aldeyra Therapeutics, Inc. (NASDAQ:ALDX). Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices. Addit...
Neutral
GlobeNewsWire
5 days ago
SAN FRANCISCO, April 24, 2025 (GLOBE NEWSWIRE) -- On April 3, 2025 investors in Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) saw the price of their shares crash over 70% after the company announced that it received a Complete Response Letter (“CRL”) from the FDA for the resubmission of the New Drug Application (“NDA”) of reproxalap, an investigational drug candidate, for the treatment of dry eye d...
Neutral
Accesswire
6 days ago
PHILADELPHIA, PA / ACCESS Newswire / April 23, 2025 / Kehoe Law Firm, P.C. is investigating potential securities fraud claims on behalf of investors of Aldeyra Therapeutics, Inc. ("Aldeyra" or the "Company") (NASDAQ:ALDX).
Neutral
GlobeNewsWire
8 days ago
NEW YORK, April 21, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against TechTarget, Inc. (NASDAQ:TTGT) and Aldeyra Therapeutics, Inc. (NASDAQ:ALDX). Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices. Addit...
Positive
Seeking Alpha
8 days ago
Aldeyra Therapeutics' stock offers a compelling contrarian opportunity, rebounding 70% after a 75% drop due to an FDA CRL for Reproxalap in dry eye disease. The FDA requested additional efficacy data. Aldeyra already has two trials with data expected in Q2 2025, aiming for NDA resubmission by mid-2025. Reproxalap targets upstream inflammation, offering rapid symptom relief in a large market, wi...
Neutral
GlobeNewsWire
8 days ago
SAN FRANCISCO, April 21, 2025 (GLOBE NEWSWIRE) -- On April 3, 2025 investors in Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) saw the price of their shares crash over 70% after the company announced that it received a Complete Response Letter (“CRL”) from the FDA for the resubmission of the New Drug Application (“NDA”) of reproxalap, an investigational drug candidate, for the treatment of dry eye d...
Neutral
GlobeNewsWire
11 days ago
SAN FRANCISCO, April 18, 2025 (GLOBE NEWSWIRE) -- On April 3, 2025 investors in Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) saw the price of their shares crash over 70% after the company announced that it received a Complete Response Letter (“CRL”) from the FDA for the resubmission of the New Drug Application (“NDA”) of reproxalap, an investigational drug candidate, for the treatment of dry eye d...

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today